Total Payments
$1.6M
2024 Payments
$343,883
Companies
36
Transactions
986
Medicare Patients
506
Medicare Billing
$58,500
Payment Breakdown by Category
Consulting$756,652 (47.6%)
Other$585,199 (36.8%)
Research$134,384 (8.5%)
Travel$83,263 (5.2%)
Food & Beverage$15,637 (1.0%)
Education$13,720 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $756,652 | 242 | 47.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $512,527 | 175 | 32.3% |
| Unspecified | $134,384 | 100 | 8.5% |
| Travel and Lodging | $83,263 | 199 | 5.2% |
| Honoraria | $48,100 | 13 | 3.0% |
| Food and Beverage | $15,637 | 243 | 1.0% |
| Education | $13,720 | 9 | 0.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $13,331 | 3 | 0.8% |
| Grant | $11,241 | 2 | 0.7% |
Payments by Type
General
$1.5M
886 transactions
Research
$134,384
100 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $435,392 | 221 | $0 (2024) |
| ABBVIE INC. | $404,924 | 279 | $0 (2024) |
| Janssen Biotech, Inc. | $140,260 | 78 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $133,908 | 74 | $0 (2024) |
| Eli Lilly and Company | $110,156 | 70 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $105,479 | 68 | $0 (2024) |
| Celgene Corporation | $46,160 | 37 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $39,937 | 23 | $0 (2023) |
| Genentech, Inc. | $39,390 | 20 | $0 (2024) |
| Gilead Sciences, Inc. | $23,883 | 14 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $343,883 | 157 | PFIZER INC. ($86,162) |
| 2023 | $281,534 | 154 | AbbVie Inc. ($128,382) |
| 2022 | $233,013 | 135 | ABBVIE INC. ($56,486) |
| 2021 | $127,826 | 76 | PFIZER INC. ($36,170) |
| 2020 | $193,605 | 93 | PFIZER INC. ($81,976) |
| 2019 | $159,829 | 123 | PFIZER INC. ($55,856) |
| 2018 | $131,213 | 136 | PFIZER INC. ($43,184) |
| 2017 | $117,953 | 112 | AbbVie, Inc. ($36,733) |
All Payment Transactions
986 individual payment records from CMS Open Payments — Page 1 of 40
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Eli Lilly and Company | OMVOH (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,150.00 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Eli Lilly and Company | OMVOH (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $9,000.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Eli Lilly and Company | OMVOH (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,200.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Eli Lilly and Company | OMVOH (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,150.00 | General |
| Category: Immunology | ||||||
| 12/16/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $3,050.00 | General |
| 12/12/2024 | PFIZER INC. | VELSIPITY (Drug) | Consulting Fee | Cash or cash equivalent | $1,540.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 12/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Consulting Fee | Cash or cash equivalent | $6,780.00 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,700.00 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Eli Lilly and Company | OMVOH (Drug) | Food and Beverage | In-kind items and services | $5.68 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $74.43 | General |
| Category: Immunology | ||||||
| 12/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | — | Cash or cash equivalent | $6,780.00 | Research |
| Study: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease • Category: INTERNAL MEDICINE | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $38.42 | General |
| Category: Immunology | ||||||
| 12/05/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: VELSIPITY CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 11/26/2024 | Genentech, Inc. | — | — | Cash or cash equivalent | $4,025.00 | Research |
| Study: UC P3: Double-Blind Treat Straight Through | ||||||
| 11/20/2024 | Eli Lilly and Company | OMVOH (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Food and Beverage | In-kind items and services | $130.80 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/18/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: VELSIPITY CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 11/18/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: VELSIPITY CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 11/15/2024 | ABBVIE INC. | — | — | In-kind items and services | $50.00 | Research |
| Study: A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease | ||||||
| 11/15/2024 | ABBVIE INC. | — | — | In-kind items and services | $50.00 | Research |
| Study: A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease | ||||||
| 11/15/2024 | ABBVIE INC. | — | — | In-kind items and services | $24.99 | Research |
| Study: A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease | ||||||
| 11/15/2024 | ABBVIE INC. | — | — | In-kind items and services | $22.63 | Research |
| Study: A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease | ||||||
| 11/13/2024 | PFIZER INC. | VELSIPITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $11,550.00 | General |
| Category: INFLAMMATION;PAIN | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $59,590 | 45 |
| ETRASIMOD CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $26,410 | 24 |
| TOFACITINIB IBD CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $15,870 | 10 |
| A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease | Takeda Pharmaceuticals U.S.A., Inc. | $13,106 | 3 |
| A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease | E.R. Squibb & Sons, L.L.C. | $9,100 | 4 |
| UC P3: Double-Blind Treat Straight Through | Genentech, Inc. | $6,440 | 3 |
| XELJANZ CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,880 | 2 |
| VELSIPITY CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $990.00 | 3 |
| PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF ETROLIZUMAB DURING INDUCTION AND MAINTENANCE IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO ARE REFRACTORY TO OR INTOLERANT OF TNF INHIBITORS. | F. Hoffmann-La Roche AG | $225.00 | 1 |
| A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease | ABBVIE INC. | $147.62 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 153 | 173 | $157,706 | $23,332 |
| 2022 | 4 | 74 | 78 | $74,589 | $11,288 |
| 2021 | 4 | 128 | 135 | $46,849 | $10,117 |
| 2020 | 5 | 151 | 157 | $119,014 | $13,762 |
Total Patients
506
Total Services
543
Medicare Billing
$58,500
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 74 | 91 | $52,214 | $12,923 | 24.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Office | 2023 | 13 | 13 | $47,357 | $4,887 | 10.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Office | 2023 | 14 | 14 | $48,472 | $3,869 | 8.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 14 | 14 | $6,304 | $1,348 | 21.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 27 | 30 | $1,044 | $250.73 | 24.0% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2023 | 11 | 11 | $2,315 | $55.36 | 2.4% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Office | 2022 | 14 | 14 | $47,001 | $4,488 | 9.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 29 | 33 | $13,602 | $3,214 | 23.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 19 | 19 | $10,559 | $2,920 | 27.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 12 | 12 | $3,427 | $666.07 | 19.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 34 | 37 | $14,589 | $3,366 | 23.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 16 | 18 | $9,690 | $2,833 | 29.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 30 | 32 | $9,089 | $1,835 | 20.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 16 | 16 | $4,241 | $1,048 | 24.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 14 | 14 | $6,112 | $953.26 | 15.6% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2021 | 18 | 18 | $3,128 | $81.60 | 2.6% |
| 45380 | Biopsy of large bowel using an endoscope | Facility | 2020 | 20 | 20 | $59,728 | $3,048 | 5.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 23 | 25 | $9,615 | $2,324 | 24.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 18 | 19 | $9,718 | $2,196 | 22.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 12 | 12 | $10,969 | $2,134 | 19.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 25 | 26 | $15,018 | $2,127 | 14.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 25 | 26 | $9,040 | $1,806 | 20.0% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2020 | 28 | 29 | $4,926 | $126.87 | 2.6% |
About David Rubin
David Rubin is a Gastroenterology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1699838102.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, David Rubin has received a total of $1.6M in payments from pharmaceutical and medical device companies, with $343,883 received in 2024. These payments were reported across 986 transactions from 36 companies. The most common payment nature is "Consulting Fee" ($756,652).
As a Medicare-enrolled provider, Rubin has provided services to 506 Medicare beneficiaries, totaling 543 services with total Medicare billing of $58,500. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Chicago, IL
- Active Since 12/18/2006
- Last Updated 10/24/2022
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1699838102
Products in Payments
- XELJANZ (Drug) $295,834
- RINVOQ (Biological) $173,853
- STELARA (Biological) $135,763
- VELSIPITY (Drug) $83,991
- SKYRIZI (Biological) $65,127
- ENTYVIO (Biological) $54,133
- ZEPOSIA (Drug) $31,533
- TREMFYA (Drug) $31,304
- Humira (Biological) $29,756
- Entyvio (Biological) $24,060
- OMVOH (Drug) $16,347
- Non-Covered Product (Drug) $16,137
- HUMIRA (Biological) $12,606
- Ozanimod (Drug) $10,449
- REMICADE (Biological) $6,483
- SIMPONI (Biological) $5,956
- ABRILADA (Biological) $5,440
- APRISO (Drug) $5,029
- Lucentis (Biological) $4,553
- Hera W10 (Device) $4,550
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Chicago
Stephen Hanauer, Md, MD
Gastroenterology — Payments: $1.6M
Gastroenterology $1.6M
Dr. Darren Brenner, M.d, M.D
Gastroenterology — Payments: $1.4M
Gastroenterology $1.4M
Steven Flamm, Md, MD
Gastroenterology — Payments: $1.3M
Gastroenterology $1.3M
Russell Cohen
Gastroenterology — Payments: $834,887
Gastroenterology $834,887
Atman Shah
Gastroenterology — Payments: $766,122
Gastroenterology $766,122
Dr. Parambir Dulai, M.b.b.s, M.B.B.S
Gastroenterology — Payments: $614,180
Gastroenterology $614,180